Lung Delivery of Advanced Lipid-Based Nanoplatform via Dry Powder Inhalers for Drugs with Poor Aqueous Solubility

Marlena Neißl – Student, Area III - Next-Generation Manufacturing / Institute of Pharmaceutical Sciences, RCPE GmbH, Graz, Austria / University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, Graz, Austria; Valerio Todaro – Senior Formulator Scientist, CHIESI Farmaceutici S.p.A., Parma, Italy; Alessandro Cavecchi – Head of Pharmaceutical Technology, CHIESI Farmaceutici S.p.A., Parma, Italy; Eleonore Fröhlich – Key Researcher / Associate Professor, Group Leader, RCPE GmbH, Graz, Austria / Medical University of Graz, Center for Medical Research, Graz, Austria; Andreas Zimmer – Head of Institute of Pharmaceutical Sciences, Full Professor, University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, Graz, Austria; Sharareh Salar-Behzadi – Key Researcher and Group Leader Material Science / associate professor, Area III - Next-Generation Manufacturing / Institute of Pharmaceutical Sciences, RCPE GmbH, Graz, Austria / University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, Graz, Austria

Introduction: Pulmonary drug delivery enables localized and targeted treatment with fast alveolar absorption while limiting systemic side effects. The delivery of poorly water-soluble active pharmaceutical ingredients (APIs) to the deep lung remains a significant challenge due to the limited range of approved pulmonary excipients. This research aims to develop a promising strategy of a carrier-free, spray-dried dry powder inhaler (DPI) formulation, utilizing lipid-based excipients (LBEs) nanoplatform to enhance API solubility, provide tailored release, and ensure high deep lung targeting biocompatibility (1).